{"schema_version":"secwatch.filing_event.v1","accession":"0001439222-22-000098","form_type":"8-K","ticker":"AGIO","cik":"0001439222","company_name":"AGIOS PHARMACEUTICALS, INC.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.666916+00:00","generated_at":"2026-06-22T08:40:57.459101+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Agios Q3 2022: PYRUKYND revenue $3.5M, 56 patients on therapy; CHMP positive opinion received","bullets":["PYRUKYND net revenue $3.5M in Q3 2022; 56 patients on therapy (+51% Q/Q), 84 patients enrolled (+64%).","Received positive CHMP opinion for PYRUKYND in adult PK deficiency; filed with UK MHRA.","Cash $1.0B as of Sept 30; subsequently received $131.8M from sale of TIBSOVO royalty rights.","Net loss from continuing ops $81.7M vs $84.3M in Q3 2021; R&D $65.0M, SG&A $29.1M.","Appointed Cecilia Jones as CFO; Rahul Ballal and Cynthia Smith to board of directors."],"urls":{"canonical":"https://secwatch.observer/filing/0001439222-22-000098","json":"https://secwatch.observer/filing/0001439222-22-000098.json","markdown":"https://secwatch.observer/filing/0001439222-22-000098.md","text":"https://secwatch.observer/filing/0001439222-22-000098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/0001439222-22-000098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/agio-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T08:40:57.459101+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d1f9edcb930db7f9ce42d2159d0aba1ea018732d","claim":"AGIOS PHARMACEUTICALS, INC. reported third quarter ended September 30, 2022 results: revenue $3.5 million, net income Net loss from continuing operations was $81.7 million.","evidence_excerpt":"Quarter 2022 Financial Results – U.S. PYRUKYND ® (mitapivat) Launch Provides Capability Building Platform to Support Expected Future Product Growth and Expansion; Net Revenue of $3.5 Million in Q3 – – Received Positive CHMP Opinion for PYRUKYND ® in Adults with Pyruvate Kinase (PK) Deficiency – – On Track to Meet Year-end Enrollment Targets in PYRUKYND ® Thalassemia","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1439222/000143922222000098/0001439222-22-000098-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Revenue","value":"$3.5 million"},{"label":"Net income","value":"Net loss from continuing operations was $81.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}